Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 15/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 14/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 14/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18673262 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL26060490 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL19375749 | 0.94 | GNAO1 (0.40) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL21372058 | 0.88 | GNAO1 (0.41) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL22023908 | 0.86 | GNAO1 (0.43) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL20012662 | 0.85 | GNAO1 (0.34) | GNAO1GNAI3GNAI1 | |
| SCHEMBL5171549 | 0.83 | CYP1A2 (0.43) | — | |
| SCHEMBL24435761 | 0.82 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL21180109 | 0.82 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL18609539 | 0.82 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, CAMKK1, CILK1 | GNAO1 1534/4885GNAI3 1021/4885GNAI1 999/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | GNAO1 1951/4885GNAI3 446/4885GNAI1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.